Pregnant women, children to miss out on new HIV/AIDS drug


By Ronald Kabuye
Ministry of health has revealed that pregnant women and children below 10 years will not be enrolled for the delutgravir drug, a new more efficacious anti HIV/AIDS drug which is also known as DTG.
The drug which also suppresses the transmission of HIV/AIDS it’s
enrollment will be in a period of 18 months.
The decision follows an advise from World Health Organization WHO due to the survey being carried out in Botswana which has indicated that the drug is dangerous to the pregnant women since it antagonize the child formation.
According to the UPHIA 2017 research 1.14 million people out of the 1.30 of people who affected with HIV/AIDS are on treatment.
This has been revealed by Joshua musinguzi from the ministry of health during the media dialogue held under the theme HIV/AIDS and the new development.
Musinguzi also has great hope that by 2020 the epidemic will be under control and by 2030 it will be a no public health threat especially due to the various intervention put in place to fight it.
Statistics indicate that the new cases of HIV/AIDS stood at 50,000 in 2017 from 130,000 in 2013.
Musinguzi further indicates that men are the most people who die of the epidemic since they tend to shun away from treatment services as opposed to their female counterparts.
This has prompted the ministry of health to put in place favorable intervention including outreach program, over time and weekend clinics amongst others.
Other intervention put in place to fight the epidemic include scaling up the ABC program which stands for abstinence, be faithful and condom use, safe male circumcision, elimination of mother to child transmission of HIV and PREP and septrin use.


Be the first to comment

Leave a Reply

Your email address will not be published.